JP2018526453A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526453A5 JP2018526453A5 JP2018531308A JP2018531308A JP2018526453A5 JP 2018526453 A5 JP2018526453 A5 JP 2018526453A5 JP 2018531308 A JP2018531308 A JP 2018531308A JP 2018531308 A JP2018531308 A JP 2018531308A JP 2018526453 A5 JP2018526453 A5 JP 2018526453A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ulbp
- cell composition
- cells
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022150822A JP7662588B2 (ja) | 2015-09-03 | 2022-09-22 | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214071P | 2015-09-03 | 2015-09-03 | |
| US62/214,071 | 2015-09-03 | ||
| PCT/US2016/050428 WO2017041106A1 (en) | 2015-09-03 | 2016-09-06 | Genetically-engineered drug resistant t cells and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022150822A Division JP7662588B2 (ja) | 2015-09-03 | 2022-09-22 | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526453A JP2018526453A (ja) | 2018-09-13 |
| JP2018526453A5 true JP2018526453A5 (https=) | 2019-10-17 |
| JP7186615B2 JP7186615B2 (ja) | 2022-12-09 |
Family
ID=58188630
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531308A Active JP7186615B2 (ja) | 2015-09-03 | 2016-09-06 | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 |
| JP2022150822A Active JP7662588B2 (ja) | 2015-09-03 | 2022-09-22 | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022150822A Active JP7662588B2 (ja) | 2015-09-03 | 2022-09-22 | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12005078B2 (https=) |
| EP (3) | EP4295914A3 (https=) |
| JP (2) | JP7186615B2 (https=) |
| KR (1) | KR20180086183A (https=) |
| CN (1) | CN108291209A (https=) |
| AU (2) | AU2016318163B2 (https=) |
| CA (1) | CA2997547A1 (https=) |
| ES (2) | ES2910709T3 (https=) |
| IL (2) | IL257763B (https=) |
| WO (1) | WO2017041106A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2496244B8 (en) | 2009-11-02 | 2017-11-22 | Emory University | Drug resistant immunotherapy for treatment of a cancer |
| KR102618373B1 (ko) * | 2016-12-09 | 2023-12-29 | 유에이비 리서치 파운데이션 | 키메라성 클로로톡신 수용체 |
| GB201715918D0 (en) * | 2017-09-29 | 2017-11-15 | Tc Biopharm Ltd | Modified CAR-T |
| EP3818148A4 (en) * | 2018-07-05 | 2022-09-28 | Emory University | TRANSDUCTION OF CONGENITAL IMMUNE COMPETENT CELLS USING AAV6 |
| MX2021000459A (es) * | 2018-07-13 | 2021-06-23 | Univ Kyoto | Metodo para producir celulas t gamma y delta. |
| US20210346430A9 (en) * | 2018-08-26 | 2021-11-11 | Oaiscell Biotechnologies | Method for treating glioblastoma |
| CA3118696A1 (en) * | 2018-11-08 | 2020-05-14 | The Uab Research Foundation | Compositions and methods for treating cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3203599B2 (ja) | 1989-10-24 | 2001-08-27 | カイロン コーポレイション | 感染性タンパク質デリバリーシステム |
| WO1997032025A1 (en) | 1996-03-01 | 1997-09-04 | Regents Of The University Of Minnesota | Method for selective engraftment of drug-resistant hematopoietic stem cells |
| US7078034B2 (en) | 1999-01-28 | 2006-07-18 | Palmetto Health Alliance | In vitro activated γ δ lymphocytes |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| KR100912994B1 (ko) | 2004-04-05 | 2009-08-21 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Ｎｋｇ２ｄ의 조절 |
| EP2496244B8 (en) * | 2009-11-02 | 2017-11-22 | Emory University | Drug resistant immunotherapy for treatment of a cancer |
| EP2694126A4 (en) | 2011-04-08 | 2014-12-10 | Rarecyte Inc | SYSTEMS AND METHOD FOR OBTAINING TARGET PARTICLES FROM A SUSPENSION |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| EP2968601A1 (en) | 2013-03-10 | 2016-01-20 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| KR102348577B1 (ko) | 2013-11-22 | 2022-01-06 | 셀렉티스 | 면역요법을 위한 화학요법 약물 저항성 ｔ―세포들의 조작 방법 |
| ES2792849T3 (es) * | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| WO2016081518A2 (en) | 2014-11-17 | 2016-05-26 | Adicet Bio, Inc. | Engineered gamma delta t-cells |
| KR102618373B1 (ko) | 2016-12-09 | 2023-12-29 | 유에이비 리서치 파운데이션 | 키메라성 클로로톡신 수용체 |
| WO2020210774A1 (en) | 2019-04-12 | 2020-10-15 | Emory University | Compositions and methods for promoting hematopoietic cell cytotoxicity |
| JP2024503507A (ja) | 2021-01-20 | 2024-01-25 | インエイトバイオ，インコーポレイテッド | 多価クロロトキシンキメラ抗原受容体 |
-
2016
- 2016-09-06 EP EP23194635.1A patent/EP4295914A3/en not_active Withdrawn
- 2016-09-06 AU AU2016318163A patent/AU2016318163B2/en active Active
- 2016-09-06 ES ES16843195T patent/ES2910709T3/es active Active
- 2016-09-06 ES ES22150671T patent/ES2965437T3/es active Active
- 2016-09-06 EP EP22150671.0A patent/EP4006146B1/en active Active
- 2016-09-06 CN CN201680060533.6A patent/CN108291209A/zh active Pending
- 2016-09-06 US US15/756,937 patent/US12005078B2/en active Active
- 2016-09-06 WO PCT/US2016/050428 patent/WO2017041106A1/en not_active Ceased
- 2016-09-06 CA CA2997547A patent/CA2997547A1/en active Pending
- 2016-09-06 JP JP2018531308A patent/JP7186615B2/ja active Active
- 2016-09-06 KR KR1020187009488A patent/KR20180086183A/ko not_active Ceased
- 2016-09-06 EP EP16843195.5A patent/EP3344760B1/en active Active
-
2018
- 2018-02-27 IL IL257763A patent/IL257763B/en active IP Right Grant
-
2021
- 2021-04-11 IL IL282220A patent/IL282220B/en unknown
-
2022
- 2022-09-19 AU AU2022235516A patent/AU2022235516A1/en not_active Abandoned
- 2022-09-22 JP JP2022150822A patent/JP7662588B2/ja active Active
-
2024
- 2024-05-03 US US18/654,622 patent/US20250073228A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526453A5 (https=) | ||
| Wang et al. | The state of the art of bispecific antibodies for treating human malignancies | |
| JP2016513458A5 (https=) | ||
| FI3313441T3 (fi) | Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla | |
| JP2021535142A5 (https=) | ||
| JP2019532997A5 (https=) | ||
| Wurz et al. | Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential | |
| FI3455259T3 (fi) | Anti-PD-1-vasta-aineiden ja sädehoidon yhdistelmä syövän hoitoon | |
| RU2018135317A (ru) | Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии | |
| JP2019519499A5 (https=) | ||
| JP7662588B2 (ja) | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 | |
| JP2020510624A5 (https=) | ||
| Burnette et al. | The immunology of ablative radiation | |
| JP2016528195A5 (https=) | ||
| JP2016520302A5 (https=) | ||
| JPWO2019157332A5 (https=) | ||
| Fares et al. | Immune checkpoint inhibitors: Advances and impact in neuro-oncology | |
| JP2021511372A5 (https=) | ||
| Garnett-Benson et al. | Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities | |
| JPWO2020047389A5 (https=) | ||
| TW201734033A (zh) | 惡性病變的組合治療 | |
| US20230270861A1 (en) | Inhibitors of the Artemin Pathway for Treatment of Cancer | |
| Beane et al. | Novel techniques and the future of HIPEC (immunotherapy, viral therapy) | |
| Malhotra et al. | Synergistic Effect of Vaccines and Chemotherapeutic Agents in Combating Different Carcinomas | |
| Keshavarz-Fathi et al. | COMBINATION THERAPY: CANCER VACCINES AND OTHER |